Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/14/2008

is characterized by the rapid proliferation (growth) of abnormal white blood cells. These cells are unable to perform their regular functions and eventually crowd out healthy red and white blood cells. Leukemia cells can also spread to other parts of the body. People afflicted with AML are susceptible to increased risk of infections, anemia and bleeding.

AML is the one of the most common forms of leukemia and occurs most often in older adults -- the average age being 65. The American Cancer Society estimates that 13,410 new cases and 8,990 deaths occurred in the United States in 2007.

Although several risk factors for AML have been identified, the specific cause of AML remains unclear. AML is a potentially curable disease; but only a minority of patients are cured with current therapies. Current treatments for AML include chemotherapy, blood transfusions and stem cell transplants.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I and Phase II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting t
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
8. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
9. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Dec. 17 Transgenomic, Inc. (OTC Bulletin ... agreement with Gene Solutions for an exclusive licensing ... in Parkinson,s disease patients that can form the ... for Parkinson,s disease. Transgenomic,s platform mitochondrial mutation detection ... a diagnostic test that evaluates and quantitates the ...
(Date:12/17/2009)... Technologies, Inc. (formerly NTII) ("NTI") announced today ... the Secretary of State of the State of ... Dissolution generally become effective upon filing. The Certificate ... under the Delaware General Corporation Law. In ... Dissolution, NTI also closed its stock transfer books ...
(Date:12/17/2009)... 17 The Dr. Paul Janssen Award ... for nominations. The $100,000 Award recognizes individuals whose ... improvement of human health. Nomination forms are ... accepted until February 15, 2010. The Award winner ... the world,s top scientists, which features three new ...
Breaking Medicine Technology:Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 2Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 3Transgenomic, Inc. Executes License Option agreement for Parkinson's Disease Diagnostic Markers with Gene Solutions, LLC 4Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 2Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 3Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research 4AHA Board Elects John Bluford Chair Elect Designate 52607 1AHA Board Elects John Bluford Chair Elect Designate 52607 2AHA Board Elects John Bluford Chair Elect Designate 52607 3Anesiva Receives NASDAQ Delisting Staff Determination Letter 13175 1Anesiva Receives NASDAQ Delisting Staff Determination Letter 13175 2Anesiva Receives NASDAQ Delisting Staff Determination Letter 13175 3Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 13174 1Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results 13174 2
... April 1 , - Trial Results Expected Mid-2008, ... on vascular diseases, eye diseases and cancer, today announces ... MIVI III trial in the,United States. This study is ... vitrectomy (MIVI III - Microplasmin for Vitreous,Injection)., A ...
... Funding, SUNNYVALE, Calif., March 31 CardioMind, ... vessels, announced,today that it has begun a First-in-Human ... trial, as it is called, began in February ... far, has led to,successful implantations in 12 patients., ...
Other Medicine Technology:ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 2ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 3ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 4CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent 2CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent 3
(Date:12/17/2009)... examined her options for birth – capturing all her wishes and ... is not accustomed to providing the kind of care she wants. ... , ... Silver Spring, MD (Vocus) December 17, 2009 -- ... her options for birth – capturing all her wishes and preferences ...
(Date:12/17/2009)... reductions; more funding needed for continued success , ... ... World Health Organization,s World Malaria Report 2009 ... included in the study have witnessed reduction in malaria cases by ... which compiles information gathered from malaria programs in 108 countries, highlights ...
(Date:12/17/2009)... Hutchinson Cancer Research Center scientist M. Elizabeth "Betz" ... distinction of AAAS Fellow. Election as a Fellow ... American Association for the Advancement of Science, or ... researcher in the Hutchinson Center,s Vaccine and Infectious ... the University of Washington. She is being honored, ...
(Date:12/17/2009)... don,t know about the secret measures could prove more ... A leading advocacy group for small businesses said that ... health care reform in the Senate is not only ... the confidence that is desperately needed to get the ... to the Small Business & Entrepreneurship Council (SBE Council), ...
(Date:12/17/2009)... -- The Department of Justice announced today that ... York have entered into settlement agreements with three ... submitted false claims to the New York Medicaid ... Medicaid program provides coverage for home health aides ... that they received proper training. The United States ...
Breaking Medicine News(10 mins):Health News:Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider 2Health News:Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider 3Health News:WHO World Malaria Report Shows Aid Efforts Are Working 2Health News:WHO World Malaria Report Shows Aid Efforts Are Working 3Health News:M. Elizabeth Halloran Named AAAS Fellow 2Health News:M. Elizabeth Halloran Named AAAS Fellow 3Health News:M. Elizabeth Halloran Named AAAS Fellow 4Health News:The Reid Bill and What We Know: Higher Taxes and Less Capital - Higher Health Costs and Red Tape for Small Business 2Health News:Three New York City Home Health Agencies Pay $9.7 Million to the United States to Settle False Claims Act Claims 2
... compounds that stimulate stem cell growth in the brain. ... appear in the September 2006 issue of The FASEB ... to restored function for people who are affected by ... wide range of neurological disorders. The researchers have explained ...
... cautioned by the health and family Welfare Minister towards ... them. // ,The minister, R Ashok has ... harassing and denying treatment to HIV/AIDS patients. He made ... celebration of ‘Ashodaya’, which is a community based organisation ...
... to launch a new vaccination project to protect ... vaccination against pneumococcal meningitis will also be integrated ... meningitis is very serious," Diane McConnell, manager of ... die or be left with very severe after ...
... meats may become reactive in the body and could affect ... have found a link between processed meats and cancer, but ... Center in New York and colleagues is the first one ... the online edition of the New Scientist. ,Barr ...
... Haikerwal, today urged all Australians to think about organ ... to donate organs.// ,Research published in the latest ... transplant are harvested from only a fraction of the ... that, in many instances, organs are not donated because ...
... revealed that the number of women suffering from gestational ... 5 years.// Hence, overweight women are being advised to ... given shocking statistics. According to it, more than 18,500 ... only 4286 cases were reported in 2000. ...
Other Medicine News:Health News:Action Against Doctors Harassing HIV/AIDS Patients 2Health News:AMA Urges Organ Donors to Speak Up 2
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: When high buckle is required. Overall length: 14.0 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
...
...
Medicine Products: